{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T12:28:50Z","timestamp":1787056130941,"version":"build-2736575974"},"reference-count":28,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jiac.2026.103038","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T23:41:51Z","timestamp":1784763711000},"page":"103038","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of oral type II topoisomerase inhibitors versus ceftriaxone-based regimens for the treatment of gonorrhoea: A systematic review and meta-analysis of randomised controlled trials"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-4624-6013","authenticated-orcid":false,"given":"Husni Mubarak","family":"Zainal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9808-9163","authenticated-orcid":false,"given":"Ricardo Soares","family":"Guimar\u00e3es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanika","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4209-6014","authenticated-orcid":false,"given":"Abdullah","family":"Al-Owesie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3940-9506","authenticated-orcid":false,"given":"Firas","family":"Abadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8557-4465","authenticated-orcid":false,"given":"Aniruddha","family":"Hazra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2026.103038_bib1","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1071\/SH19061","article-title":"Epidemiology of gonorrhoea: a global perspective","volume":"16","author":"Kirkcaldy","year":"2019","journal-title":"Sex Health"},{"key":"10.1016\/j.jiac.2026.103038_bib3","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41572-019-0128-6","article-title":"Gonorrhoea","volume":"5","author":"Unemo","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jiac.2026.103038_bib4","first-page":"388","article-title":"Chlamydial and gonococcal infections: screening, diagnosis, and treatment","volume":"105","author":"Yonke","year":"2022","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.jiac.2026.103038_bib5","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1071\/SH19023","article-title":"World health organization global gonococcal antimicrobial surveillance program (WHO GASP): review of new data and evidence to inform international collaborative actions and research efforts","volume":"16","author":"Unemo","year":"2019","journal-title":"Sex Health"},{"key":"10.1016\/j.jiac.2026.103038_bib7","doi-asserted-by":"crossref","first-page":"735","DOI":"10.3201\/eid2404.171873","article-title":"Cooperative recognition of internationally disseminated ceftriaxone-resistant Neisseria gonorrhoeae strain","volume":"24","author":"Lahra","year":"2018","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.jiac.2026.103038_bib8","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1128\/CMR.00010-14","article-title":"Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future","volume":"27","author":"Unemo","year":"2014","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jiac.2026.103038_bib9","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1177\/09564624251345195","article-title":"British Association of Sexual Health and HIV UK national guideline for the management of infection with Neisseria gonorrhoeae, 2025","volume":"36","author":"Fifer","year":"2025","journal-title":"Int J STD AIDS"},{"key":"10.1016\/j.jiac.2026.103038_bib11","series-title":"Updated recommendations for the treatment of Neisseria gonorrhoeae, Chlamydia trachomatis and Treponema pallidum (syphilis), and new recommendations on syphilis testing and partner services","year":"2024"},{"key":"10.1016\/j.jiac.2026.103038_bib12","doi-asserted-by":"crossref","first-page":"22","DOI":"10.37757\/MR2018.V20.N3.6","article-title":"Effectiveness of a serogroup B and C meningococcal vaccine developed in Cuba","volume":"20","author":"Ochoa-Azze","year":"2018","journal-title":"MEDICC Rev"},{"key":"10.1016\/j.jiac.2026.103038_bib13","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.3201\/eid2206.151093","article-title":"Ecologic study of meningococcal B vaccine and Neisseria gonorrhoeae infection, Norway","volume":"22","author":"Whelan","year":"2016","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.jiac.2026.103038_bib14","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/infdis\/jiae383","article-title":"Effectiveness of MenB-4C vaccine against gonorrhea: a systematic review and meta-analysis","volume":"231","author":"Abara","year":"2025","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jiac.2026.103038_bib15","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/nature09197","article-title":"Type IIA topoisomerase inhibition by a new class of antibacterial agents","volume":"466","author":"Bax","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.jiac.2026.103038_bib16","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01221-18","article-title":"Microbiological analysis from a phase 2 randomised study in adults evaluating single oral doses of gepotidacin in the treatment of uncomplicated urogenital gonorrhoea caused by Neisseria gonorrhoeae","volume":"62","author":"Scangarella-Oman","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2026.103038_bib17","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1056\/NEJMoa1706988","article-title":"Single-dose zoliflodacin (ETX0914) for treatment of urogenital gonorrhoea","volume":"379","author":"Taylor","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiac.2026.103038_bib18","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/cid\/ciy145","article-title":"Gepotidacin for the treatment of uncomplicated urogenital gonorrhoea: a phase 2, randomised, dose-ranging, single oral dose evaluation","volume":"67","author":"Taylor","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2026.103038_bib19","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/S0140-6736(25)00628-2","article-title":"Oral gepotidacin for the treatment of uncomplicated urogenital gonorrhoea (EAGLE-1): a phase 3 randomised, open-label, non-inferiority, multicentre study","volume":"405","author":"Ross","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.jiac.2026.103038_bib21","article-title":"Zoliflodacin versus ceftriaxone plus azithromycin for treatment of uncomplicated urogenital gonorrhoea: an international, randomised, controlled, open-label, phase 3, non-inferiority clinical trial","volume":"11","author":"Luckey","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.jiac.2026.103038_bib20","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jiac.2026.103038_bib22","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.jiac.2026.103038_bib23","series-title":"Review Manager (RevMan) [computer program]. Version 5.4","year":"2020"},{"key":"10.1016\/j.jiac.2026.103038_bib24","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1136\/bmj.39500.677199.AE","article-title":"Grading quality of evidence and strength of recommendations for diagnostic tests and strategies","volume":"336","author":"Sch\u00fcnemann","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.jiac.2026.103038_bib25","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.jiac.2026.103038_bib26","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0895-4356(99)00161-4","article-title":"Publication bias in meta-analysis: its causes and consequences","volume":"53","author":"Thornton","year":"2000","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jiac.2026.103038_bib27","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1002\/sim.1461","article-title":"Adjusting for publication bias in the presence of heterogeneity","volume":"22","author":"Terrin","year":"2003","journal-title":"Stat Med"},{"key":"10.1016\/j.jiac.2026.103038_bib28","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2022.27.34.2200081","article-title":"Trends and regional variations of gonococcal antimicrobial resistance in the Netherlands, 2013\u20132019","volume":"27","author":"Visser","year":"2022","journal-title":"Euro Surveill"},{"key":"10.1016\/j.jiac.2026.103038_bib29","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s40265-021-01530-0","article-title":"Epidemiology, treatments, and vaccine development for antimicrobial-resistant Neisseria gonorrhoeae: current strategies and future directions","volume":"81","author":"Lin","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.jiac.2026.103038_bib30","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1021\/acsinfecdis.0c00021","article-title":"Zoliflodacin: an oral spiropyrimidinetrione antibiotic for the treatment of Neisseria gonorrhoeae, including multidrug-resistant isolates","volume":"6","author":"Bradford","year":"2020","journal-title":"ACS Infect Dis"},{"issue":"1","key":"10.1016\/j.jiac.2026.103038_bib31","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X26001364?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X26001364?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T11:41:58Z","timestamp":1787053318000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X26001364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1341321X26001364"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2026.103038","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of oral type II topoisomerase inhibitors versus ceftriaxone-based regimens for the treatment of gonorrhoea: A systematic review and meta-analysis of randomised controlled trials","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2026.103038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103038"}}